The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2024 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today. The key is whether management indicates that the reported period is stale relative to the operating present, with concrete things already in motion. In the transcript, management discusses several developments that are ongoing or just completed after the quarter. For example: - PRESERVE study enrollment completed in Q1, but data submission to FDA is in Q3 calendar 2024, so that's future. - APEX PE study is 75% enrolled, completion expected soon, but that's future. - Breakthrough designation for AngioVac received, but study design finalization in Q2, future. - Auryon CE Mark expected in next few months, future. - New product launches for AlphaVac second gen in calendar 2024, future. However, management also notes that the quarter's results include some items that are not representative? They mention that the quarter's results exclude divested businesses, but that's a pro forma adjustment. They also mention that the quarter had a shift in equity grant timing, but that's a one-time item. But the question is: does management convey that the reported period's numbers are behind the current business? They talk about improvements and momentum, but they also give guidance for the full year that is consistent with the quarter's performance. They don't explicitly say that the quarter's results understate the current run rate. They do mention that AngioVac grew sequentially, but that's within the quarter. The key is whether management points to concrete things already in place that are not reflected in the quarter. For example, they mention that they enrolled the final patient in PRESERVE during Q1, but that's a milestone, not revenue. They mention that they received breakthrough designation, but that's a regulatory status. They also mention that they are seeing improvements in the business, but they don't say that the quarter's numbers are stale. They provide guidance for the year that is in line with the quarter's performance. I think the answer is NO. The call is a standard results discussion with forward-looking statements, but management does not indicate that the reported period is not representative of the current business. They are not saying that the business has moved to a different level than the print.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.